Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Azevan Pharmaceuticals logo — Innovative therapies for stress, mood, and behavior disorder...

Azevan Pharmaceuticals

Innovative therapies for stress, mood, and behavior disorders

Founded 1999 5 employees Venture round Total: $2.21M Biotechnology, Health Care +2

General Information

Company Name Azevan Pharmaceuticals
Founded Year 1999
Founders / Decision Makers
Team member
Employees 5
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Azevan Pharmaceuticals. To contact Azevan Pharmaceuticals, visit azevan.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Azevan Pharmaceuticals compare?

A PDF of Azevan Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Azevan Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Azevan Pharmaceuticals

Azevan Pharmaceuticals is a clinical stage company focused on developing small molecule drugs to treat disorders related to stress, mood, and behavior. With a dedication to inhibiting the effects of arginine vasopressin, a peptide neurohormone associated with conditions such as major depression, intermittent explosive disorder, impulse control and anger disorders, as well as post-traumatic stress disorder (PTSD), the company aims to address unmet needs in mental health. Their product offerings, SRX251 and SRX246, are CNS-penetrating V1a receptor antagonists designed for oral administration, targeting stress-related CNS disorders including depression, PTSD, and intermittent explosive disorders. Formerly known as Serenix Pharmaceuticals, LLC, the company rebranded to Azevan Pharmaceuticals, Inc. in January 2002 and was founded in 1999. The company secured a $2.21M Venture Round investment on 18 October 2013 to further its innovative therapies. Headquartered in Bethlehem, Pennsylvania, Azevan Pharmaceuticals operates within the Biotechnology, Health Care, and Pharmaceutical industries.

Business keywords: pharmaceuticals, drug development, clinical stage, neurohormone, mood disorders, behavior disorders, small molecule drugs, arginine vasopressin, depression treatment, PTSD treatment, stress-related disorders, CNS-penetrating antagonists, mental health, bioavailability, Bethlehem, Pennsylvania

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $2.21M -
18 Oct 2013

Azevan Pharmaceuticals Alternatives & Competitors

View All Alternatives
Azevan Pharmaceuticals vs
XWPharma
XWPharma United States

Neuroscience biotech developing novel therapeutics for sleep, neuropsych, and other underserved CNS...

Series C
16 employees
Biotechnology, Health Care
Azevan Pharmaceuticals vs
InMed Pharmaceuticals
InMed Pharmaceuticals Canada

Global leader in the manufacturing and development of rare cannabinoids. Our subsidiary is Baymedica...

Post-IPO Equity
18 employees
Biotechnology, Health Care
Azevan Pharmaceuticals vs
Proniras Corporation
Proniras Corporation United States

Clinical-stage biotechnology developing therapeutics for the treatment of substance use & specialty...

Series B
4 employees
Biotechnology, Health Care
View all alternatives

FAQ About Azevan Pharmaceuticals

Innovative therapies for stress, mood, and behavior disorders
Azevan Pharmaceuticals was founded in 1999.
Azevan Pharmaceuticals operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on pharmaceuticals, drug development, clinical stage and neurohormone.
Azevan Pharmaceuticals has approximately 5 employees.
Azevan Pharmaceuticals has completed 1 funding round, raising a total of $2.21M. The latest funding stage is Venture round.
Top alternatives and competitors to Azevan Pharmaceuticals include XWPharma, InMed Pharmaceuticals, Proniras Corporation, Developing New Drugs for AML and PDAC, Astex Pharmaceuticals . These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Azevan Pharmaceuticals and XWPharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Azevan Pharmaceuticals, https://bouncewatch.com/company/azevan-pharmaceuticals, updated 13 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout